|
Jul 25
|
Cytokinetics to Announce Second Quarter Results on August 8, 2024
|
|
Jul 25
|
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Jul 23
|
Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
|
|
Jun 12
|
Insider Sale at Cytokinetics Inc (CYTK) by EVP of Research & Development
|
|
Jun 10
|
Insider Sale: Director Muna Bhanji Sells Shares of Cytokinetics Inc (CYTK)
|
|
Jun 5
|
Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks
|
|
Jun 5
|
Insider Sale: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK)
|
|
May 29
|
Cytokinetics to Participate in June Investor Conferences
|
|
May 28
|
Cytokinetics Announces Closing of Public Offering of Common Stock
|
|
May 27
|
Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now?
|
|
May 24
|
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
|
|
May 23
|
Cytokinetics secures up to $575M in royalty deal, frustrating investors
|
|
May 23
|
Cytokinetics Announces Pricing of Public Offering of Common Stock
|
|
May 22
|
Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline
|
|
May 22
|
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
|
|
May 22
|
Cytokinetics Announces Proposed Public Offering of Common Stock
|
|
May 22
|
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
|
|
May 15
|
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
|
|
May 13
|
Health Care Roundup: Market Talk
|
|
May 13
|
Cytokinetics Slumps Despite 'Pristine' Results For Bristol Myers-Rivaling Heart Drug
|